Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ocular Therapeutix Inc OCUL

Healthcare
Ocular Therapeutix, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye. Its first commercial drug product, DEXTENZA, is for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular... see more

Recent & Breaking News (NDAQ:OCUL)

Ocular Therapeutix™ to Present at the Cowen and Company 39th Annual Health Care Conference

Business Wire March 5, 2019

Ocular Therapeutix™ To Report Fourth Quarter and Year End 2018 Financial Results

Business Wire March 1, 2019

Ocular Therapeutix™ Prices $37.5 Million Subordinated Convertible Debt Financing

Business Wire February 21, 2019

Ocular Therapeutix™ Announces Dosing of First Patient in OTX-TKI (tyrosine kinase inhibitor implant) Phase 1 Clinical Trial for the Treatment of Wet Age-related Macular Degeneration (AMD)

Business Wire February 20, 2019

Detailed Research: Economic Perspectives on Inovalon, Merit Medical, Senseonics, Ocular Therapeutix, The Hartford Financial Services Group, and Synopsys — What Drives Growth in Today's Competitive Landscape

GlobeNewswire January 22, 2019

The Daily Biotech Pulse: Agile Gives Regulatory Update On Contraceptive Patch, Advaxis Misses Estimates, Ocular Submits sNDA

Benzinga.com  January 11, 2019

Ocular Therapeutix™ Submits Supplemental New Drug Application (sNDA) for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Inflammation Following Ophthalmic Surgery

Business Wire January 10, 2019

Purdue Pharma L.P. and Ocular Therapeutix, Inc. Announce Initiation of Collaborative Research Activities to Evaluate Innovative Formulations for Non-Opioid Treatments for Pain

Business Wire January 7, 2019

5 Stocks To Watch For December 31, 2018

Benzinga.com  December 31, 2018

Ocular Therapeutix™ Announces Completion of Debt Refinancing

Business Wire December 28, 2018

Ocular Therapeutix™ Added to Nasdaq Biotechnology Index

Business Wire December 20, 2018

Ocular Therapeutix™ Announces the Hiring of Chad Brines, Vice President, Sales

Business Wire December 6, 2018

Mid-Morning Market Update: Markets Open Higher; Nexstar to buy Tribune Media for $46.50/Share

Benzinga.com  December 3, 2018

Ocular Therapeutix™ Announces FDA Approval of DEXTENZA® for the Treatment of Ocular Pain Following Ophthalmic Surgery

Business Wire December 3, 2018

Ocular Therapeutix™ to Present at the 30th Annual Piper Jaffray Healthcare Conference

Business Wire November 21, 2018

Ocular Therapeutix™ Reports Third Quarter 2018 Financial Results and Business Update

Business Wire November 7, 2018

Ocular Therapeutix™ To Report Third Quarter 2018 Financial Results

Business Wire October 31, 2018

Ocular Therapeutix™ Receives FDA Warning Letter Related to ReSure® Sealant

Business Wire October 19, 2018

Ocular Therapeutix™ to Present at the 2018 Cantor Global Healthcare Conference

Business Wire September 26, 2018

Ocular Therapeutix™ to Present at the H.C. Wainwright 20th Annual Global Investment Conference

Business Wire August 29, 2018